Call Number (LC) Title Results
HE 20.4208/2:An 8/11 Guidelines for the clinical evaluation of antineoplastic drugs. 1
HE 20.4208/2:B 78 Guidelines for the clinical evaluation of bronchodilator drugs. 1
HE 20.4208/2:C 19 Guidelines for the clinical evaluation of drugs to prevent dental caries. 1
HE 20.4208/2:C 61 General considerations for the clinical evaluation of drugs. 1
HE 20.4208/2:G 21 Guidelines for the clinical evaluation of gastric secretory depressant (GSD) drugs. 1
HE 20.4208/2:G 21/2 Guidelines for the clinical evaluation of G.I. motility-modifying drugs. 1
HE 20.4208/2:H 99 Guidelines for the clinical evaluation of hypnotic drugs. 1
HE 20.4208/2:In 3 General considerations for the clinical evaluation of drugs in infants and children. 1
HE 20.4208/2:L 45 Guidelines for the clinical evaluation of laxative drugs. 1
HE 20.4208/2:L 66 Guidelines for the clinical evaluation of lipid-altering agents in adults and children. 1
HE 20.4208/2:Os 7 Guidelines for the clinical evaluation of drugs used in the treatment of osteoporosis. 1
HE 20.4208/2:P 41 Guidelines for the clinical evaluation of drugs to prevent, control and/or treat periodontal disease. 1
HE 20.4208/2:P 95 Guidelines for the clinical evaluation of psychoactive drugs in infants and children. 1
HE 20.4208/2:R 11 Guidelines for the clinical evaluation of radiopharmaceutical drugs. 1
HE 20.4208/2:R 11/rev Guidelines for the clinical evaluation of radiopharmaceutical drugs / 1
HE 20.4208:Ad 9 Guideline for postmarketing reporting of adverse drug reactions, [docket no. 85D-0249] : draft. 1
HE 20.4208:An 8 Guideline for the format and content of the summary for new drug and antibiotic applications. 1
HE 20.4208:An 8/2 Guideline on formatting, assembling, and submitting new drug and antibiotic applications. 1
HE 20.4208:Ar 2 Guideline for the submission in microfiche of the archival copy of an application. 1
HE 20.4208:C 42 Guideline for the format and content of the chemistry, manufacturing, and controls section of an application. 1